Reckitt Benckiser Healthcare (uk) Limited

Reckitt Benckiser (uk) Limited

Frank Chadwick Hampson

Peter William Dettmar

Ian Gordon Jolliffe

Edvar Onsoyen

Paul Andrew Dickson

Paul Frederick Field

Peter Edward Ross

Raffaele Del Buono

Ase Hanne Kristensen

Paul Murray McPherson

Duncan Quinell MacKenzie Craig

Douglas Banning

William Peers

Massimo Pignatelli

Ian Gordon Jollife

A pharmaceutical composition is provided for use in the healing of cells containing about 0.0001 percent weight per volume (% w/v) to about 2% w/v of an alginic acid or a salt of alginic acid having a molecular weight in the range of greater than about 250,000 to about 1,000,000, provided that if the composition additionally contains an alginic acid or a salt of alginic acid having a molecular weight in the range of about 20,000 to about 250,000, it is present in an amount of less than 1% w/w. The use of the pharmaceutical composition for the healing cells in a mammal, preferably mucosal cells is also provided.

Pharmaceutical compositions including alginates and methods of preparing and using same

Pharmaceutical compositions having improved bioadhesive properties are produced by combining an alginate, xanthan gum and/or a carageenan gum and a glucomannan and/or a galactomannan. The composition can provide both a protecting and a healing effect on mucosal surface.

Compositions for treatment of disorders of the oesophagus

An aqueous pourable liquid composition comprising a high concentration of sodium alginate and an alkali metal bicarbonate, wherein the sodium alginate has an average mannuronic acid residue to guluronic acid residue ratio of at least 0.6:1. In addition, an alginate or alginic acid for forming a protective coating on gastrointestinal mucosal tissue, use of and compositions including the same are provided.

Pourable alginate compositions

Mucoadhesive granules of carbomer suitable for oral administration of drugs

Growing community of inventors

Hedon, United Kingdom

Frank Chadwick Hampson